Zolpidem oral spray - Amherst Pharmaceuticals

Drug Profile

Zolpidem oral spray - Amherst Pharmaceuticals

Alternative Names: Zolpidem tartrate oro-mucosal spray - Amherst; Zolpimist

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator NovaDel Pharma
  • Developer Amherst Pharmaceuticals
  • Class Acetamides; Hypnosedatives; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Insomnia
  • No development reported Sleep maintenance insomnia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Sleep-maintenance-insomnia in USA (Transmucosal, Spray)
  • 29 Apr 2016 Biomarkers information updated
  • 22 Sep 2014 Amherst Pharmaceuticals acquires patents, trademarks and license agreements related to zolpidem oral spray
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top